Richard Ian Griffiths - 08 Jan 2025 Form 4 Insider Report for Silence Therapeutics plc (SLN)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLN	American Depositary Shares	Purchase	+30,000	+0.33%	9,118,667	08 Jan 2025	Ordinary Shares	90,000	$6.48	Direct	F1
transaction	SLN	American Depositary Shares	Purchase	+150,000	+1.6%	9,268,667	17 Jan 2025	Ordinary Shares	450,000	$5.35	By Cream Capital Limited	F1, F2
transaction	SLN	American Depositary Shares	Purchase	+25,000	+0.27%	9,293,667	21 Jan 2025	Ordinary Shares	75,000	$5.20	By Cream Capital Limited	F1, F2
transaction	SLN	American Depositary Shares	Purchase	+20,000	+0.22%	9,313,667	21 Jan 2025	Ordinary Shares	60,000	$5.48	By Cream Capital Limited	F1, F2
transaction	SLN	American Depositary Shares	Purchase	+12,226	+0.13%	9,325,893	23 Jan 2025	Ordinary Shares	36,678	$5.35	By Cream Capital Limited	F1, F2
transaction	SLN	American Depositary Shares	Purchase	+92,774	+0.99%	9,418,667	13 Feb 2025	Ordinary Shares	278,322	$4.29	By Cream Capital Limited	F1, F2
transaction	SLN	American Depositary Shares	Purchase	+60,000	+0.64%	9,478,667	13 Feb 2025	Ordinary Shares	180,000	$4.17	Direct	F1
transaction	SLN	American Depositary Shares	Purchase	+60,000	+0.63%	9,538,667	18 Feb 2025	Ordinary Shares	180,000	$4.85	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.
F2	The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.